BioWorld1d
Bioheng Therapeutics’ CD7-targeted universal CAR T-cell therapy gains IND clearance
Bioheng Therapeutics US LLC has obtained IND approval from the FDA for CTD-402, a CD7-targeted universal CAR T-cell therapy, ...
Nasdaq1mon
Humacyte Plans IND Filing for Small-Diameter ATEV Following Positive Preclinical Results in CABG Applications
Humacyte, Inc. announced plans to file an Investigational New Drug (IND) application with the FDA, aiming to conduct first-in-human clinical trials of its small-diameter acellular tissue ...
WAVY-TV1mon
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the FDA, including agreements reached with the agency. To date only the 6.0mm configuration ...
Nasdaq1mon
Humacyte To Submit IND Application For Small-Diameter ATEV In Coronary Bypass Surgery
(RTTNews) - Humacyte, Inc. (HUMA), a biotechnology company, Tuesday announced its plan to file an Investigational New Drug or IND application with the U.S. FDA in 2025 to support a first-in-human ...
Stockhouse1mon
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV(TM) for Coronary Artery Bypass Grafting
The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the FDA, including agreements reached with the agency. To date only the 6.0mm ...
manilatimes1mon
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
The Company's current plans for filing an IND are based on the outcome of a recent meeting held with the FDA, including agreements reached with the agency. To date only the 6.0mm configuration of the ...